MARKET

TECH

TECH

Bio-Techne Corp
NASDAQ
63.21
-1.30
-2.02%
After Hours: 63.21 0 0.00% 16:12 04/30 EDT
OPEN
63.83
PREV CLOSE
64.51
HIGH
64.78
LOW
63.16
VOLUME
1.30M
TURNOVER
0
52 WEEK HIGH
89.91
52 WEEK LOW
51.66
MARKET CAP
9.94B
P/E (TTM)
45.60
1D
5D
1M
3M
1Y
5Y
Bio-Techne Board Expansion and Strategic Director Appointments
TipRanks · 15h ago
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Bio-Techne Corporation (NASDAQ:TECH) does have debt on its balance sheet. The balance sheet is the area to focus on when analysing a company's risk. Debt is often used to assist a business until it is unable to pay it off. Bio-techne has debt of US$447.0m but its EBIT covers its interest expense 24.3 times over. The company has a low net debt to EBITDA ratio of 0.96.
Simply Wall St · 17h ago
What to Watch in the Day Ahead - Wednesday, May 1
U.S. Federal Reserve's decision on interest rates is due in the day. Pfizer will report first-quarter results before markets open. The ADP National Employment report is expected to show private payrolls rose by 175,000 in April. A flurry of data is scheduled to be released in the U.S., including the manufacturing PMI for April.
Reuters · 17h ago
Bio-Techne Q3 2024 Earnings Preview
Bio-Techne Corporation (TECH) is scheduled to announce Q3 earnings results on Wednesday, May 1st, before market open. The consensus EPS Estimate is $0.46 and the consensus revenue estimate is $292.75M. Over the last 2 years, TECH has beaten EPS estimates 25% of the time.
Seeking Alpha · 20h ago
Notable earnings before Wednesday's open
Major earnings expected before the bell on Wednesday include: Ares Capital, CVS Health, Barrick Gold, Mastercard and Pfizer. Other notable earnings slated for release before Wednesday's open include: YUM, Ares Capital and Ares Capital. For Seeking Alpha's earnings season calendar, click here.
Seeking Alpha · 21h ago
BIO-TECHNE CORP: FOLLOWING APPOINTMENT, BOARD OF BIO-TECHNE WILL BE TEMPORARILY COMPRISED OF ELEVEN DIRECTORS
Reuters · 1d ago
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
Reuters · 1d ago
Press Release: BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
Bio-Techne Corporation appoints Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab. She will serve as a member of the Science and Technology Committee.
Dow Jones · 1d ago
More
About TECH
Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Webull offers BIO-TECHNE Corp stock information, including NASDAQ: TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.